Compare Atmos Energy Corporation (ATO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Summit Therapeutics Inc — how do they compare? Atmos Energy Corporation trades at $168.76 (market cap $28.59B), while Summit Therapeutics Inc trades at $15.16 (market cap $12.06B). The key difference: Atmos Energy Corporation is far larger — about 2.4× Summit Therapeutics Inc's market cap, and Atmos Energy Corporation pays a 2.36% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ATO | SMMT | |
|---|---|---|
Market Cap | $28.59B | $12.06B |
Sector | Utilities | Health |
52-Week High | $192.25 | $26.98 |
52-Week Low | $162.44 | $12.55 |
Enterprise Value | $38.40B | $11.39B |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $169.58, up 0.99% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong Q3 2026 earnings of $1.43 per share, beating estimates, and reaffirmed fiscal 2026 guidance. Revenue grew to $4.7 billion in 2025, with a net income margin of 28.5%, while the balance sheet shows $25.19 billion in total assets and manageable leverage.
The outlook is supported by consistent dividend payments and analyst consensus pointing to upside with a $190.57 price target. Key risks include high capital expenditure trends and interest rate sensitivity, but the utility's defensive profile and earnings momentum provide a stable investment case for income-focused shareholders.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
